Oncimmune Historical Income Statement

ONC Stock   1.75  0.74  29.72%   
Historical analysis of Oncimmune Holdings income statement accounts such as Total Revenue of 3.3 M can show how well Oncimmune Holdings plc performed in making a profits. Evaluating Oncimmune Holdings income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Oncimmune Holdings's future profits or losses.
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Oncimmune Holdings plc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Oncimmune Holdings plc is a good buy for the upcoming year.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncimmune Holdings plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

About Oncimmune Income Statement Analysis

Oncimmune Holdings plc Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Oncimmune Holdings shareholders. The income statement also shows Oncimmune investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Oncimmune Holdings Income Statement Chart

At present, Oncimmune Holdings' Total Revenue is projected to increase significantly based on the last few years of reporting. The current year's Other Operating Expenses is expected to grow to about 7.4 M, whereas Selling General Administrative is forecasted to decline to about 1.9 M.

Total Revenue

Total revenue comprises all receipts Oncimmune Holdings plc generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Oncimmune Holdings plc. It is also known as Oncimmune Holdings overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Cost Of Revenue

Cost of Revenue is found on Oncimmune Holdings plc income statement and represents the costs associated with goods and services Oncimmune Holdings provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Net Income Applicable To Common Shares

The net income that remains after preferred dividends have been deducted, available to common shareholders.
Most accounts from Oncimmune Holdings' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Oncimmune Holdings plc current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncimmune Holdings plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
At present, Oncimmune Holdings' Total Revenue is projected to increase significantly based on the last few years of reporting. The current year's Other Operating Expenses is expected to grow to about 7.4 M, whereas Selling General Administrative is forecasted to decline to about 1.9 M.
 2022 2023 2024 2025 (projected)
Interest Expense2.0M711K817.7K656.3K
Depreciation And Amortization981K263K302.5K324.7K

Oncimmune Holdings income statement Correlations

0.74-0.040.250.250.3-0.16-0.240.25-0.140.10.33-0.23-0.250.39-0.28-0.230.0-0.510.50.59-0.05
0.74-0.250.390.350.20.02-0.09-0.07-0.020.220.17-0.19-0.570.410.06-0.280.23-0.790.140.69-0.11
-0.04-0.25-0.1-0.230.76-0.87-0.760.64-0.780.180.83-0.760.04-0.85-0.56-0.67-0.390.460.420.320.32
0.250.39-0.10.770.350.210.3-0.270.330.670.240.17-0.070.06-0.090.16-0.07-0.320.30.51-0.45
0.250.35-0.230.77-0.080.490.52-0.020.560.06-0.120.43-0.030.330.030.47-0.23-0.50.390.28-0.06
0.30.20.760.35-0.08-0.83-0.730.32-0.710.70.97-0.8-0.17-0.67-0.55-0.77-0.140.140.370.7-0.1
-0.160.02-0.870.210.49-0.830.94-0.550.94-0.31-0.870.940.130.730.490.90.07-0.32-0.23-0.47-0.27
-0.24-0.09-0.760.30.52-0.730.94-0.481.0-0.18-0.790.980.410.680.50.940.06-0.23-0.21-0.39-0.25
0.25-0.070.64-0.27-0.020.32-0.55-0.48-0.45-0.340.45-0.440.16-0.22-0.2-0.33-0.16-0.020.350.350.63
-0.14-0.02-0.780.330.56-0.710.941.0-0.45-0.18-0.770.980.40.730.490.930.07-0.29-0.17-0.33-0.26
0.10.220.180.670.060.7-0.31-0.18-0.34-0.180.54-0.3-0.06-0.35-0.18-0.360.190.090.050.55-0.51
0.330.170.830.24-0.120.97-0.87-0.790.45-0.770.54-0.84-0.18-0.68-0.62-0.78-0.240.140.420.65-0.05
-0.23-0.19-0.760.170.43-0.80.940.98-0.440.98-0.3-0.840.470.70.460.970.01-0.14-0.19-0.51-0.22
-0.25-0.570.04-0.07-0.03-0.170.130.410.160.4-0.06-0.180.470.130.060.49-0.130.410.05-0.260.06
0.390.41-0.850.060.33-0.670.730.68-0.220.73-0.35-0.680.70.130.490.630.3-0.62-0.16-0.08-0.1
-0.280.06-0.56-0.090.03-0.550.490.5-0.20.49-0.18-0.620.460.060.490.330.73-0.32-0.6-0.040.1
-0.23-0.28-0.670.160.47-0.770.90.94-0.330.93-0.36-0.780.970.490.630.33-0.13-0.11-0.13-0.56-0.18
0.00.23-0.39-0.07-0.23-0.140.070.06-0.160.070.19-0.240.01-0.130.30.73-0.13-0.28-0.530.280.07
-0.51-0.790.46-0.32-0.50.14-0.32-0.23-0.02-0.290.090.14-0.140.41-0.62-0.32-0.11-0.280.19-0.480.01
0.50.140.420.30.390.37-0.23-0.210.35-0.170.050.42-0.190.05-0.16-0.6-0.13-0.530.190.250.1
0.590.690.320.510.280.7-0.47-0.390.35-0.330.550.65-0.51-0.26-0.08-0.04-0.560.28-0.480.250.05
-0.05-0.110.32-0.45-0.06-0.1-0.27-0.250.63-0.26-0.51-0.05-0.220.06-0.10.1-0.180.070.010.10.05
Click cells to compare fundamentals

Oncimmune Holdings Account Relationship Matchups

Oncimmune Holdings income statement Accounts

202020212022202320242025 (projected)
Depreciation And Amortization740K197K981K263K302.5K324.7K
Interest Expense954K943K2.0M711K817.7K656.3K
Selling General Administrative5.7M7.1M434K1.7M2.0M1.9M
Total Revenue3.7M3.9M1.2M2.7M3.1M3.3M
Gross Profit2.9M1.5M792K1.2M1.4M769.5K
Other Operating Expenses8.9M12.4M5.4M6.0M6.9M7.4M
Operating Income(5.1M)(8.6M)(4.2M)(3.2M)(2.9M)(3.0M)
Ebit(5.2M)(7.4M)(5.4M)(3.3M)(2.9M)(3.1M)
Research Development1.5M1.7M1.6M1.5M1.3M0.0
Ebitda(4.5M)(7.2M)(4.4M)(3.0M)(2.7M)(2.8M)
Cost Of Revenue865K2.4M360K1.5M1.7M1.8M
Total Operating Expenses8.0M10.0M5.0M4.5M5.1M6.7M
Income Before Tax(5.7M)(9.5M)(5.9M)(4.0M)(3.6M)(3.8M)
Total Other Income Expense Net(551K)(943K)(1.7M)(749K)(674.1K)(707.8K)
Net Income(4.6M)(9.5M)4.1M(3.6M)(3.3M)(3.4M)
Income Tax Expense(1.1M)(17K)223K(477K)(429.3K)(450.8K)
Net Income From Continuing Ops(4.6M)(9.5M)(6.2M)(3.5M)(3.1M)(3.3M)
Net Income Applicable To Common Shares(8.0M)(8.5M)(4.6M)(9.5M)(8.6M)(9.0M)
Tax Provision(1.1M)(17K)223K(477K)(548.6K)(576.0K)
Net Interest Income(551K)(943K)(1.8M)(694K)(624.6K)(655.8K)
Interest Income111K403K0.017K19.6K18.6K
Reconciled Depreciation740K1.4M981K263K302.5K287.3K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Oncimmune Stock

Oncimmune Holdings plc Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Oncimmune Holdings shareholders. The income statement also shows Oncimmune investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).